摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3,4,4-Tetramethylazetidin-2-thione | 128694-25-7

中文名称
——
中文别名
——
英文名称
3,3,4,4-Tetramethylazetidin-2-thione
英文别名
3,3,4,4-tetramethylazetidine-2-thione;3,3,4,4-tetramethylazetidinthione;Tetramethylazetidinethione
3,3,4,4-Tetramethylazetidin-2-thione化学式
CAS
128694-25-7
化学式
C7H13NS
mdl
——
分子量
143.253
InChiKey
JACYTTNFMWBTRN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    44.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    参考文献:
    名称:
    1,3-Dipolar cycloadditions of 2-ethoxy- and 2-(ethylthio)-1-azetines with nitrile oxides and nitrile ylides
    摘要:
    DOI:
    10.1016/s0040-4039(00)94351-x
  • 作为产物:
    描述:
    3,3,4,4-四甲基-2-氮杂环丁酮劳森试剂 作用下, 以 四氢呋喃 为溶剂, 以89%的产率得到3,3,4,4-Tetramethylazetidin-2-thione
    参考文献:
    名称:
    2-乙氧基和2-(乙硫基)-1-氮杂环丁烷与腈,氧化物,腈和亚胺的1,3-偶极环加成反应:1,2,4-三唑的意外形成。
    摘要:
    2-乙氧基和2-(乙硫基)-1-氮杂环丁烷容易与腈氧化物和腈发生1,3-偶极环加成反应,得到稳定的4,5-双环环加合物。然而,对于腈亚胺,取决于腈亚胺N-取代基的性质,形成了预期的1,3-偶极环加合物和/或未预期的开环产物,即1,2,4-三唑。相反,氮杂环丁烷不能与腈硫化物,甲亚胺基亚胺,硝酮,芳基叠氮化物和各种二烯反应。
    DOI:
    10.1016/s0040-4020(01)85755-0
点击查看最新优质反应信息

文献信息

  • Process for the preparation of azabicyclo compounds
    申请人:Roussel Uclaf
    公开号:US05086170A1
    公开(公告)日:1992-02-04
    A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen, alkyl and hydroxyalkyl of 1 to 5 carbon atoms and amino, n is an integer from 1 to 3, X and X.sub.1 are individually selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms or taken together with the carbon atom to which they are attached are ##STR2## Y is --O-- or --S--, R.sub.3 is alkyl of 1 to 3 carbon atoms or aryl of 6 to 8 carbon atoms, ##STR3## is selected from the group consisting of ##STR4## R.sub.4 and R.sub.5 are individually aryl unsubstituted or substituted with at least one member of the group consisting of halogen, --NO.sub.2 and alkyl and alkoxy of 1 to 3 carbon atoms and non-toxic, pharmaceutically acceptable salts thereof with acids and bases having cyclooxygenase inhibiting and antibiotic acitvity.
    从以下化合物组中选择的一种化合物,其中该化合物的分子式为##STR1##其中,R.sub.1和R.sub.2分别从氢,1至5个碳原子的烷基和羟基烷基以及氨基中选择,n为1至3的整数,X和X.sub.1分别从氢和1至3个碳原子的烷基中选择,或者与它们附着的碳原子一起被选为##STR2##Y是--O--或--S--,R.sub.3是1至3个碳原子的烷基或6至8个碳原子的芳基,##STR3##从以下组中选择:##STR4##R.sub.4和R.sub.5单独为芳基,未取代或取代至少一种来自卤素,--NO.sub.2和1至3个碳原子的烷基和烷氧基的组成成员,以及具有环氧合酶抑制和抗生素活性的无毒、药学上可接受的酸和碱盐。
  • Azabicyclo compounds
    申请人:Roussel Uclaf
    公开号:US05059596A1
    公开(公告)日:1991-10-22
    A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen, alkyl and hydroxyalkyl of 1 to 5 carbon atoms and amino, n is an integer from 1 to 3, X and X.sub.1 are individually selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms or taken together with the carbon atom to which they are attached are >C.dbd.O Y is --O-- or --S--, R.sub.3 is alkyl of 1 to 3 carbon atoms or aryl of 6 to 8 carbon atoms, ##STR2## is selected from the group consisting of ##STR3## R.sub.4 and R.sub.5 are individually aryl unsubstituted or substituted with at least one member of the group consisting of halogen, --NO.sub.2 and alkyl and alkoxy of 1 to 3 carbon atoms and non-toxic, pharmaceutically acceptable salts thereof with acids and bases having cyclooxygenase inhibiting and antibiotic activity.
    从以下化合物组中选择一种化合物:##STR1## 其中R.sub.1和R.sub.2分别选择自1至5个碳原子的氢、烷基、羟基烷基和氨基的群组,n是1至3的整数,X和X.sub.1分别选择自1至3个碳原子的氢和烷基,或与它们连接的碳原子一起选择>C.dbd.O,Y为--O--或--S--,R.sub.3为1至3个碳原子的烷基或6至8个碳原子的芳基,##STR2## 选择自以下组:##STR3## R.sub.4和R.sub.5分别为非取代或取代至少一个卤原子、--NO.sub.2和1至3个碳原子的烷基和烷氧基的芳基,以及与酸和碱形成的非毒性、药学上可接受的盐,具有环氧合酶抑制和抗生素活性。
  • US5059596A
    申请人:——
    公开号:US5059596A
    公开(公告)日:1991-10-22
  • US5086170A
    申请人:——
    公开号:US5086170A
    公开(公告)日:1992-02-04
  • 1,3-dipolar cycloadditions of 2-Ethoxy- and 2-(ethylthio)-1-azetines with nitrile oxides, nitrile ylides and nitrilimines: An unexpected 1,2,4-triazole formation.
    作者:Karl Hemming、Abdul-Bassett N. Luheshi、Alan D. Redhouse、Robert K. Smalley、J.Robin Thompson、Peter D. Kennewell、R. Westwood
    DOI:10.1016/s0040-4020(01)85755-0
    日期:1993.1
    1,3-dipolar cycloadditions with nitrile oxides and nitrile ylides to give stable 4,5-bicyclic cycloadducts. With nitrilimines, however, the expected 1,3-dipolar cycloadducts and/or unexpected ring-opened products, namely 1,2,4-triazoles, are formed depending on the nature of the nitrilimine N-substituent. In contrast, the azetines fail to react with nitrile sulphides, azomethine ylides, nitrones, aryl
    2-乙氧基和2-(乙硫基)-1-氮杂环丁烷容易与腈氧化物和腈发生1,3-偶极环加成反应,得到稳定的4,5-双环环加合物。然而,对于腈亚胺,取决于腈亚胺N-取代基的性质,形成了预期的1,3-偶极环加合物和/或未预期的开环产物,即1,2,4-三唑。相反,氮杂环丁烷不能与腈硫化物,甲亚胺基亚胺,硝酮,芳基叠氮化物和各种二烯反应。
查看更多

同类化合物

己二酸,聚合1,3-二异氰酸基甲基苯,2-乙基-2-(羟甲基)-1,3-丙二醇,1,3-异苯并呋喃二酮,2,2'-氧代二[乙醇]和1,2-丙二醇 四氢吡咯-2-硫酮 吡咯烷-2,5-二硫酮 3,3-二甲基吡咯烷-2,5-二硫酮 2-甲基-2-丙基[(3S)-2-硫代-3-氮杂环丁基]氨基甲酸酯 2-氮杂双环[2.2.1]庚-5-烯-3-硫酮 1-甲氧基-5,5-二甲基吡咯烷-2-硫酮 1-甲基氮杂环十二烷-2-硫酮 1-甲基氮杂环十三烷-2-硫酮 (S)-5-乙基-2-硫代吡咯烷酮 3-(furan-3-ylmethyl)-3-methylpyrrolidine-2-thione 7,11-diethyl-2,3-dithio-1,4,7,11-tetrazacyclotridecane 8,11-diethyl-2,3-dithio-1,4,8,11-tetrazacyclotetradecane 6-methoxy-7-methylsulfanyl-3,4-dihydro-2H-[1,4]thiazepine-5-thione 5,5-Dimethylpyrrolidin-2-thion ((2S,3S)-2-Methyl-4-thioxo-azetidin-3-yl)-carbamic acid tert-butyl ester (7R,8S)-8-[(1R)-(tert-butyl-dimethyl-silanyloxy)-ethyl]-6-thia-1-azabicyclo[5.2.0]non-3-en-9-thione 5-ethyl-pyrrolidine-2-thione 1-Methyl-2-thioxo-azonan-4-one 3-Adamantan-1-yl-3-hydroxy-1-methyl-azetidine-2-thione 2,3,3-trimethyl-5-thioxo-pyrrolidine-2-carbonitrile tetrahydro-3(R)-propyl-(2H)-1,4-thiazepine-5-thione N-[(E)-5-chloropent-1-enyl]pyrrolidine-2-thione 5,5,9,9-Tetramethyl-3-thioxo-2-<3-(trimethylsilyl)propyl>-2-azaspiro<3.5>nonan-1-on 4-methylpyrrolidine-2-thione 5-Butyl-2-thiopyrrolidon 2,2,4-Trimethyl-imidazolin-5-thion 1-hydroxy-5,5-dimethylpyrrolidine-2-thione (-)-(5S)-5-(Chloromethyl)-2-thiopyrrolidinone ((S)-5-Thioxo-pyrrolidin-2-yl)-acetonitrile 4(R)-[1'(S)-[tert-(butoxycarbonyl)amino]ethyl]pyrrolidinone-2-thione 4-Ethoxy-1-methyl-1,5-dihydro-2H-pyrrole-2-thione 5-heptylpyrrolidine-2-thione 3,3,4,4-Tetramethylazetidin-2-thione (S)-5-<(tert-Butyl)dimethylsilyloxy>methyl-2-thiopyrrolidinone 3,3-Di-tert-butyl-4-(3,3-di-tert-butyl-2-oxo-4-thioxo-1-azetidinylthio)-azet-2(3H)-on 4-Hydroxymethylpyrrolidin-2-thion 5,5,9,9-Tetramethyl-3-(5,5,9,9-tetramethyl-1-oxo-3-thioxo-2-azaspiro<3.5>non-2-ylthio)-2-azaspiro<3.5>non-2-en-1-on (R)-5-((Z)-non-2-enyl)pyrrolidine-2-thione 7-({[t-butyl(dimethyl)silyl]oxy}methyl)-7-methyl-1,4-thiazepane-5-thione 7-azabicyclo<4.2.0>octan-8-thione 5-pentyl-2-thiopyrrolidone tetrahydro-3(S)-propyl-(2H)-1,4-thiazepine-5-thione (S)-4,5-dihydro-5-hydroxymethylpyrrole-2(3H)-thione 5-propyl-2-thiopyrrolidone octahydro-azecine-2-thione raphanusamide cis-3-(methylthio) methylene-2-pyrrolidinethione trans-3-(methylthio) methylene-2-pyrrolidinethione [1,4]thiazepane-5-thione